Blue Belt Technologies

prior investment

HealthpointCapital is a values-driven, research-based private equity firm
exclusively focused on the musculoskeletal sector — specifically orthopedics and dental. HealthpointCapital manages in excess of $800 million of institutional capital.

Orthopedic & Dental Industry Research Most Recent Blog Articles

Musculoskeletal News Roundup 20-Nov-14 BY ANDREW VAHRADIAN, NOVEMBER 20, 2014

Medtronic reports financial results...Histogenics files proposed IPO range...Axiomed Spine sold by investors...CoorsTek Medical to acquire Nanosurfaces Industries...Update on Zimmer's proposed acquisition of Biomet...Aurora Spine, Spineart receive product clearance...Bacterin listing update...Blue Belt receives Frost & Sullivan's 2014 Global Enabling Technology Leadership Award for Navio device...Biomet, Exactech product updates...Royal Oak Medical, Stryker product launches...Dignity Health settlement...IlluminOss, Zyga Technology clinical updates...Bone Therapeutics and Kasios enter collaboration more

Blue Belt Technologies Receives Frost & Sullivan’s 2014 Global Enabling Technology Leadership Award BY EDITOR, NOVEMBER 20, 2014

Blue Belt Technologies, a robotic-assisted surgical technology company, announced that it has received Frost & Sullivan’s 2014 Global Enabling Technology Leadership Award in Orthopedic Surgery. The award represents Blue Belt’s achievements for superior leadership, technological innovation, customer service, and strategic... more

Dental News Roundup Aug - Oct 2014 BY MATTHEW JAFFE, NOVEMBER 19, 2014

ALGN, XRAY, HSIC, STMN, ZMH report earnings...Henry Schein Funding...M&A from Nobel Biocare, Henry Schein, Straumann, and Keystone Industries...Product Introductions from BioHorizons, Align, MicroDental and 3M ESPE ... Legal news from Nobel... Operations news from Dentsply, and Henry Schein... Collaboration news from Bregal Partners and Dental Partners, and from Straumann and Patterson Dental... Education news from Sirona more

Histogenics Proposes Terms for IPO BY ANDREW VAHRADIAN, NOVEMBER 18, 2014

Histogenics filed to raise between $56 million and $64 million through a previously announced initial public offering (IPO), by offering 4.3 million shares of common stock at a proposed price range of $13-$15 a share. At the midpoint of the... more

Complete Archive »

Search the HealthpointCapital Site